Patent ID: 7653428

Claim:
A method of monitoring the effectiveness of a therapeutic intervention in a person suffering from or at risk for developing an amyloidogenic disorder, the method comprising detecting a polypeptide aggregate in a supranuclear or deep cortical region of an ocular lens, wherein said polypeptide aggregate comprises an amyloid protein selected from the group consisting of β-amyloid precursor protein (APP), Aβ, Aβ 1-42 , prion protein, α-synuclein, and fragments thereof and wherein said polypeptide aggregate is detected using an ophthalmic instrument sensitive to light scattering; and monitoring the amount, the rate, or both the amount and the rate of aggregation over time; wherein a decrease in the amount, the rate, or both the amount and rate of protein aggregation over time following therapeutic intervention indicates that the therapeutic intervention has clinical benefit.